The NGS-based companion diagnostic test conducted in the present study analyzed KRAS, NRAS, and BRAF together as a panel of CRC molecular targets; therefore, it has the advantages of requiring fewer specimens and being more time and cost efficient in determining the optimal regimen for each patient. Here, KRAS is linked to colorectal carcinoma.